All
Botox has long duration of action for Tx of axillary hyperhidrosis
May 1st 2004Washington - Intradermal botulinum toxin type A (Botox) for the treatment of primary axillary hyperhidrosis produces a durable effect, with nearly half of patients requiring only one treatment over a one-year period, according to study data released at the annual meeting of the American Academy of Dermatology here.
Not all topical anesthetics are alike
May 1st 2004Waikoloa, Hawaii - The increase in the number of topical anesthesia options available mandates that dermatologists consider how they compare with respect to efficacy, safety, and patient convenience when selecting an agent to minimize the pain of a cutaneous procedure, said Dina N. Anderson, M.D., at the recent annual Hawaii Dermatology Seminar.
Antimicrobial dressingsretooled for the present
May 1st 2004Washington - The phrase "what is old is new again" aptly describes the current status of antimicrobial dressings, which, thanks to a new generation of products, are making a comeback in the woundcare arena, said Marketa Limova, M.D., at the annual meeting of the American Academy of Dermatology.
Long-term outcome of juvenile dermatomyositis rests on early treatment with immunosuppresants
May 1st 2004Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Oral tazarotene shows sustained efficacy in psoriasis
May 1st 2004Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.
Oral tazarotene delivers lasting results
May 1st 2004Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.
Rethinking recruitment & retention
May 1st 2004National report - Aware of a shortage of medical personnel in the Philadelphia region, physician assistant Abby Jacobson was confident she would easily land a new job when she found out her supervising physician was selling his practice. She not only got a new position within a few weeks at a dermatology practice, but she received a salary increase, and negotiated a four-day workweek with Fridays off.
Aastrom Biosciences Inc. receives Phase I Small Business Innovation Research Grant (SBIR)
April 22nd 2004Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.
United Research Laboratories and Mutual Pharmaceutical Co. launch generic version of Periostat
April 16th 2004Source: www.drugfacts.com United Research Laboratories / Mutual Pharmaceutical Co. announced the launch of a generic version of CollaGenex Pharmaceutical Inc.?s Periostat (doxycycline hyclate) tablets.
Ceplene/Interleukin-2 combination approved for treatment of malignant melanoma
April 14th 2004Source: www.pharmalive.com Maxim Pharmaceuticals announced that its treatment protocol to provide its investigational drug Ceplene, in combination with interleukin-2 (IL-2), for treatment of patients with advanced malignant melanoma, has been approved by the FDA. The protocol allows Maxim to provide expanded access of Ceplene to patients in the United States while a Phase III clinical trial continues.
FDA accepts Connetics Corp. NDA filing for Extina
April 8th 2004Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.